Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patientswith schizophrenia

Human Psychopharmacology

Volumn 24, Issue 4, 2009, Pages 301-308

  Yagihashi, Tatsuhiko ^a   Mizuno, Masafumi ^b   Chino, Bun ^a   Sato, Yuji ^a   Sakuma, Kei ^c   Takebayashi, Toru ^a   Takao, Takahashi ^a   Kosaki, Kenjiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Asaka Hospital   (Japan)

Author keywords

CYP2D6; Pharmacogenetics; Risperidone; Schizophrenia

Indexed keywords

AMITRIPTYLINE; BROMPERIDOL; CHLORPROMAZINE; CIMETIDINE; CYTOCHROME P450 2D6; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; MAPROTILINE; MEXILETINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; RISPERIDONE; TERBINAFINE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ALLELE; ANALYSIS OF VARIANCE; ARTICLE; ASIAN; CONTROLLED STUDY; DNA MICROARRAY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MUTANT; PRIORITY JOURNAL; SCHIZOPHRENIA; ADULT; BLOOD; CLASSIFICATION; DRUG COMBINATION; GENETICS; METABOLISM; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; REGRESSION ANALYSIS; RISPERIDONE; SCHIZOPHRENIA;

EID: 68049129639     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1025     Document Type: Article

References (44)

1. Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP. 1999. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 21: 105-115.
2. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. 2002. Molecular genetics of CYP2 D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53: 111-122.
3. Brachtendorf L, Jetter A, Beckurts KT, Holscher AH, Fuhr U. 2002. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 90: 144-149.
4. Bradford LD. 2002. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3: 229-243.
5. Castberg I, Helle J, Aamo TO. 2005. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 27: 680-682.
6. Cho HY, Lee YB. 2006. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res 29: 525-533.
7. Chouinard G, Arnott W. 1993. Clinical review of risperidone. Can J Psychiatry 38 (Suppl 3): S89-S95.
8. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. 1995. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274: 516-520.
9. D'Arrigo C, Migliardi G, Santoro V, et al. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res 52: 497-501.
10. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. 2005. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15-27.
11. de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. 2007. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40: 93-102.
12. DeVane CL, Nemeroff CB. 2001. An evaluation of risperidone drug interactions. J Clin Psychopharmacol 21: 408-416.
13. Ereshefsky L. 1996. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57 (Suppl 11): 12-25.
14. Fang J, Bourin M, Baker GB. 1999. Metabolism of risperidone to 9hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147-151.
15. Fontana E, Dansette PM, Poli SM. 2005. Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6: 413-454.
16. Fukuda T, Nishida Y, Imaoka S, et al. 2000. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380: 303-308.
17. Gossen D, de Suray JM, Vandenhende F, Onkelinx C, Gangji D. 2002. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 4: E11.
18. Hara Y, Nakajima M, Miyamoto KI, Yokoi T. 2005. Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions. Xenobiotica 35: 549-560.
19. Heller T, Kirchheiner J, Armstrong VW, et al. 2006. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit 28: 673-677.
20. Heykants J, Huang ML, Mannens G, et al. 1994. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55 (Suppl): 13-17.
21. Huang ML, Van Peer A, Woestenborghs R, et al. 1993. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257-268.
22. Iwashima K, Yasui-Furukori N, Kaneda A, et al. 2007. No association between CYP2D6 polymorphisms and personality trait in Japanese. Br J Clin Pharmacol 64: 96-99.
23. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. 1988. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685-693.
24. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46: 452-459.
25. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. 1988. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661-670.
26. Llerena A, Berecz R, Dorado P, et al. 2003. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J Chromatogr B Analyt Technol Biomed Life Sci 783: 213-219.
27. Madeira M, Levine M, Chang TK, Mirfazaelian A, Bellward GD. 2004. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metab Dispos 32: 460-467.
28. Mihara K, Kondo T, Yasui-Furukori N, et al. 2003. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25: 287-293.
29. Murray M. 2006. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58: 871-885.
30. Nakagami T, Yasui-Furukori N, Saito M, et al. 2005. Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction. J Clin Psychopharmacol 25: 89-91.
31. Prior TI, Baker GB. 2003. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28: 99-112.
32. Ramamoorthy Y, Tyndale RF, Sellers EM. 2001. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11: 477-487.
33. Regenthal R, Kunstler U, Hesse S, Sabri O, Preiss R. 2005. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. Int J Clin Pharmacol Ther 43: 370-378.
34. Remmerie BM, Sips LL, de Vries R, et al. 2003. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 783: 461-472.
35. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L. 2001. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57: 671-675.
36. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML. 1999. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 147: 300-305.
37. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia A. 2001. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23: 223-227.
38. Spina E, Martines C, Caputi AP, et al. 1991. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 41: 467-470.
39. Suzuki A, Otani K, Ishida M, et al. 1997. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit 19: 261-264.
40. Suzuki Y, Someya T, Shimoda K, et al. 2001. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther Drug Monit 23: 363-368.
41. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. 1999. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65: 570-575.
42. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. 2004. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by p-glycoprotein. Int J Neuropsychopharmacol 7: 415-419.
43. Yasui-Furukori N, Saito M, Inoue Y, et al. 2007. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 63: 51-56.
44. Yu A, Kneller BM, Rettie AE, Haining RL. 2002. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303: 1291-1300.